Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aanonsen N, Lensing M, Prietz R (2004) Utproevende behandling med snetralstimulerende legemidler tol vokse men hyperkinetisk forstyrrelse/ADHD. Ullevaal University Hospital, Oslo
American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 41(suppl 2):26S–49S
Angold A, Erkanli A, Egger HL, Costello EJ (2000). Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39:975–984 (discussion 984–994)
Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ (2006) Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 27:1–10
Barkley R, Fischer M, Edelbrock C, Smallish L (1991) The adolescent outcome of hyperactive children diagnosed by research criteria—III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 32(2):233–255
Barkley R, Guevremont D, Anastopoulos A, DuPaul G, Shelton T (1993) Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 92(2):212–218
Barkley RA, Murphy KR, Kwasnik D (1996) Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 98(6):1089–1095
Buitelaar J (2002) Epidemiological aspects: what have we learned over the last decade? In: Sandberg S (ed) Hyperactivity and attention disorders of childhood. Cambridge University Press, Cambridge, pp 30–64
Bussing R, Zima B, Mason D, Hou W, Wilson Garvan C, Forness S (2005) Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adoles Psychopharmacol 15:78–87
Buurma H, Bouvy M, De Smet P, Floor-Schreudering A, Leufkens H, Egberts A (2008) Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 33:17–23
Capone N, McDonnel T (2006) Medication persistence among agents used to treat attention-deficit/hyperactivity disorder, diabetes, and elevated serum cholesterol. In: American Psychiatric Association 2006 annual meeting. American Psychiatric Association, Toronto
Castle L, Aubert R, Verbrugge R, Khalid M, Epstein R (2007) Trends in medication treatment for ADHD. J Atten Disord 10:335–342
Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J (2008) Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adoles Psychiatry Mental Health 2:31–46
de Ridder T, Bruffaerts R, Danckaerts M, Bonnewyn A, Demyttenaere K (2008) ADHD in de Belgische bevolking; een epidemiologische exploratieve studie. Tijdschrift voor Psychiatrie 8:499–508
DeBar LL, Lynch F, Powell J, Gale J (2003) Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatrics Adoles Med 157:150–157
DiScala C, Lescohier I, Barthel M, Li G (1998) Injuries to children with attention deficit hyperactivity disorder. Pediatrics 102(6):1415–1421
Donker G, Groenhof F, van der Veen W (2005) Toenemend aantal voorschriften voor methylfenidaat in huisartsenpraktijken in Noordoost-Nederland, 1998–2003. Nederlands Tijdschrift voor Geneeskunde 149:1742–1747
DosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL (2005) Multiple psychotropic medication use for youths: a two-state comparison. J Child Adoles Psychopharmacol 15:68–77
Faber A, van den Jong de-Berg L, van den Berg van den P, Tobi H (2005) Psychotropic co-medication among stimulant-treated children in the Netherlands. J Child Adoles Psychopharmacol 15:38–43
Faraone S, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow up studies. Psychol Med 36:159–165
Fischer M, Barkley R, Edelbrock C, Smallish L (1990) The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 58(5):580–588
Gagnon B, Low G, Schreyer G (2005) Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30:100–107
Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS (2008) National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69:131–140
http://www.keele.ac.uk/schools/pharm/MTRAC/ProductInfo/verdicts/A/ATOMOXETINE.PDF
Hugtenburg J, Heerdink E, Egberts A (2005) Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol 60:377–379
Kessler R, Adler L, Ames M, Barkley R, Birnbaum H, Greenberg P, Johnston J, Spencer T, Ustun T (2005) The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565–572
Kooij J (2003) ADHD bij volwassenen. Inleiding in diagnostiek en behandeling. ADHD in adults. Introduction and treatment. Swets & Zeitlinger Publishers, Lisse
Lage M, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adoles Psychopharmacol 14:575–581
Layton D, Souverein P, Heerdink E, Shakir S, Egberts A (2008) Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users. A cohort study using pharmacy dispensing data in the Netherlands. Drug Safety 31:143–158
Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC (2001) Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J Am Med Assoc 285(1):60–66
Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993) Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565–576
Marcus S, Wan G, Kemner J, Olfson M (2005) Continuity of methylphenidate treatment for attention deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572–578
Miller A, Lalonde C, McGrail K, Armstrong R (2001) Prescription of methylphenidate to children and youth, 1990–1996. Can Med Assoc 165:1489–1494
Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A (2008) Trends in psychostimulant and antidepressant use by children in 2 canadian provinces. La Revue de Psychiatry 53:152–159
Multidisciplinaire Richtlijn ADHD bij kinderen en jeugdigen (2005) Richtlijn voor diagnostiek en behandeling van ADHD bij kinderen en jeugdigen (Multidisciplinairy Guideline for diagnosis and treatment of ADHD of children and adolescents). Trimbos Instituut, Utrecht
Murphy K, Barkley R (1996) Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. J Atten Disord 3:147–161
Olfson M, Marcus M, Zhang H, Wan G (2007) : Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharmacy 13:570–577
Pauw R, Dieleman H, de Vogel de E, Eussen M (2008) Retrospectief, observationeel onderzoek naar switchen en stoppen van ADHD-medicatie. Pharmaceutisch Weekblad, Wetenschappelijk Platform 2:183–187
Pohl GM, Van Brunt DL, Ye W, Stoops WW, Johnston JA (2009) A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 8:95–103
Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD (2007) Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Aust N Z J Public Health 31:120–126
Prosser B, Reid R (2009) Changes in use of psychostimulant medication for ADHD in South Australia (1990–2006). Aust N Z J Psychiatry 43:340–347
Reid R, Hakendorf P, Prosser B (2002) Use of stimulant medication for ADHD in South Australia. J Am Acad Child Adoles Psychiatry 41:906–913
Robison L, Sclar D, Traer T, Galins R (1999) National trends in prevalence of attention-deficit/hyperactivity disorder and the prescription of methylphenidate among school-age children: 1990–1995. Clin Pediatr 38:209–217
Robison L, Sclar D, Skaer T (2005) Trends in ADHD and stimulant use among adults: 1995–2002. Psychiatr Serv 56:1497
Safer DJ, Krager JM (1994) The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics 94:462–464
Scheffler R, Hinshaw S, Modrek S, Levine P (2007) The global market for ADHD medications. Health Aff 26:450–457
Schirm E, Tobi H, Zito J, van den Jong de-Berg L (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25–E29
Sobanski E, Sabljic D, Alm B, Skopp G, Kettler N, Mattern R, Strohbeck-Kühner P (2008a) Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). J Neural Trans 115:347–356
Sobanski E, Brüggemann D, Alm B, Kern S, Philipsen A, Schmalzried H, Hesslinger B, Waschkowski H, Rietschel M (2008b) Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 23:142–149
Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463
Ten Have M, de Graaf R, Dorsselaer S, Verdurmen J, Land van’t H, Vollenbergh W, Ormel J (2006) Prevalentie van impulsstoornissen. Resultaten van the European Study of Epidemiology of Mental Disorders (ESEMeD). Trimbos Instituut, Utrecht
Thompson J, Varley C, McClellan J, Hilt R, Lee T, Kwan A, Lee T, Trupin E (2009) Second opinions improve ADHD prescribing in a medicaid-insured community population. J Am Acad Child Adoles Psychiatry 48:740–748
Trip A, Visser S, Kalverdijk L, de Jong-van den Berg L (2009) Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 67:466–468
van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T (2010) Trends in incidence and characteristics of children, adolescents and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adoles Psychopharmacol 20:55–61
Vinker S, Vinker R, Elhayany A (2006) Prevalence of methylphenidate use among Israeli children: 1998–2004. Clin Drug Invest 26:161–167
Vitiello B (2008) An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 20:121–126
Wilens TE (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283–301
Winterstein A, Gerhard T, Shuster J, Zito J, Johnson M (2008) Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Ann Pharmacother 42:24–31
Zito J, Safer D, dosReis S, Gardner J, Boles M, Lynch F (2000) Trends in prescribing of psychotropic medications to preschoolers. J Am Med Assoc 283:1025–1030
Zito J, Safer D, Satish Valluri M, Gardner J, Korelitz J, Mattison D (2007) Psychotherapeutic medication prevalence in medicaid-insured preschoolers. J Child Adoles Psychopharmacol 17:195–203